adyn, a Seattle, WA-based precision medicine company, closed a $2.5m seed round of funding.
The round was co-led by Lux Capital and M13 with participation from Civilization Ventures, Concrete Rose Capital, Y Combinator, Madrona Pioneer Fund, Ascend VC, and angel investors including Anne Wojcicki of 23andMe, Nish Bhat of Color Genomics, Qasar Younis of Applied Intuition, and Ashley Mayer of Glossier.
The company intends to use the funds to continue to expand operations and its business reach.
Led by founder Dr. Elizabeth Ruzzo, who received her Ph.D in genetics and genomics from Duke University and spent over 10 years researching and identifying genetic risk for complex diseases such as epilepsy and autism, adyn is a precision medicine company that provides medically actionable scientific insights and empowers individuals to proactively optimize their health—from birth control, to fertility, and beyond.
adyn’s flagship product, the Birth Control Optimization Test, aims to quantify hormone baseline levels and assess genetic risk for two of the most serious side effects: blood clots and depression. adyn then integrates this with medical history and side effect profiles of estrogens and progestins used in hormonal contraception. adyn’s trained birth control specialists share personalized recommendations and are available for ongoing care through adyn’s telemedicine platform.